Llwytho...
Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime
The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose melphalan with autologous stem cell transplant (HDM-ASCT). In 2015 alone, the US Food and Drug Administration (FDA) approved 4 novel drugs for MM. Novel drug...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Adv Hematol Oncol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7451402/ https://ncbi.nlm.nih.gov/pubmed/31730582 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|